Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $323.00

Krystal Biotech (NASDAQ:KRYS) had its target price lifted by Chardan Capital from $220.00 to $323.00 in a research note released on Wednesday morning, Marketbeat.com reports. They currently have a buy rating on the stock.

A number of other research firms have also recently issued reports on KRYS. The Goldman Sachs Group raised their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. HC Wainwright reissued a “buy” rating and issued a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. Jefferies Financial Group boosted their price objective on Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a report on Tuesday. Zacks Research downgraded Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Finally, TD Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $318.75.

Krystal Biotech Trading Down 0.3%

Shares of NASDAQ KRYS opened at $261.80 on Wednesday. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $298.30. The stock has a 50 day moving average of $265.50 and a 200-day moving average of $209.66. The company has a market capitalization of $7.65 billion, a P/E ratio of 38.22 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The business had revenue of $107.11 million for the quarter, compared to analysts’ expectations of $105.30 million. Analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, CAO Kathryn Romano sold 12,500 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the transaction, the chief accounting officer owned 19,318 shares in the company, valued at $5,257,200.52. This trade represents a 39.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This represents a 1.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 13.70% of the stock is currently owned by insiders.

Institutional Trading of Krystal Biotech

Large investors have recently modified their holdings of the stock. Avoro Capital Advisors LLC raised its stake in Krystal Biotech by 4.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock valued at $712,226,000 after purchasing an additional 111,111 shares in the last quarter. State Street Corp increased its holdings in Krystal Biotech by 10.5% in the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock valued at $186,306,000 after buying an additional 128,639 shares during the period. Soleus Capital Management L.P. increased its holdings in Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after buying an additional 481,200 shares during the period. Braidwell LP raised its position in shares of Krystal Biotech by 81.6% in the 2nd quarter. Braidwell LP now owns 727,811 shares of the company’s stock valued at $100,045,000 after buying an additional 327,067 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Krystal Biotech by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock valued at $85,174,000 after buying an additional 7,194 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Key Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: KRYS reported a quarterly earnings beat (Feb. 17) — EPS and revenue topped consensus, which drove an initial gap up in shares after the print. That strong operational result supports higher near-term momentum for the stock. Krystal Biotech Shares Gap Up After Earnings Beat
• Positive Sentiment: Chardan Capital raised its price target to $323, signaling continued institutional enthusiasm from some brokers and providing upside narrative against the recent pullback. Chardan Boosts KRYS Price Target to $323
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $310 target, indicating that at least one major analyst house still views medium-term upside despite model revisions. HC Wainwright Coverage
• Neutral Sentiment: Analyst commentary pieces are reframing KRYS after recent data and target resets — these articles summarize shifting expectations around the Vyjuvek commercial ramp and pipeline positioning, useful context but not direct catalysts. Why Analysts See KRYS Story Shifting Reassessing KRYS After Rally and Pipeline Focus
• Neutral Sentiment: Reported short-interest figures appear to be erroneous/zero (entries show 0 shares and 0.0 days-to-cover). Because the data is clearly inconsistent, it is unlikely to be a reliable trading signal today.
• Negative Sentiment: HC Wainwright materially trimmed EPS forecasts across FY2026–FY2028 (e.g., FY2026 cut from ~$7.41 to $5.78 and FY2027 from ~$10.21 to $6.52), reducing modeled growth and future earnings upside — a clear negative for valuation expectations even though the firm kept its Buy rating. HC Wainwright Estimates and Revisions

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.